| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6070290 | Journal of the American Academy of Dermatology | 2015 | 10 Pages |
Abstract
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe psoriasis and improving health-related quality of life with a comparable safety profile over 16 weeks.
Keywords
PASI 100PASI 90TNFsecukinumabPASI 75HRQOLMedDRAustekinumabSAEDLQIInvestigator Global AssessmentIgAinterleukinsuperiorityPASIMedical Dictionary for Regulatory ActivitiesDermatology Life Quality Indexadverse eventSerious adverse eventtumor necrosis factorpsoriasis area and severity indexplaque psoriasisClinical trialHealth-related quality of life
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Diamant MD, Andrew MD, MBA, Kristian MD, Tsen-Fang MD, Francisco MD, Külli MD, PhD, Michael MD, BSc, Andreas MD, Sophie MSc, Ruquan MSc, Marina MD,